Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million
Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

October 03, 2025

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.

Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén, Joacim Malmqvist and Rebecka Björnestedt.

Related

Vinge advises Hallbyggarna Jonsereds in conjunction with the acquisition of Renthall

 Hallbyggarna Jonsereds AB, part of the NSS Group, has acquired Renthall i Sverige AB, which has a turnover of SEK 40 million.
October 02, 2025

Vinge has advised in connection with the sale of Täby Air Maintenance AB and three Saab 2000 aircraft

 Vinge has advised Erik Thun AB in connection with the sale of all shares in Täby Air Maintenance AB and three Saab 2000 aircraft to Wingefors Depå Sju AB.
October 02, 2025

Vinge advises Tengbom in connection with the acquisition of Suunnittelemo

 Tengbom Finland is expanding and has established operations in Finland through the acquisition of Suunnittelemo Oy in Tammerfors.
October 01, 2025